Biomarkers in Axial Spondyloarthritis and TNF-α Blocker Treatment
Author Information
Author(s): Heiner Appel, Louise Janssen, Joachim Listing, René Heydrich, Martin Rudwaleit, Joachim Sieper
Primary Institution: Charité Berlin, Campus Benjamin Franklin
Hypothesis
The study investigates the relationship between inflammation, bone destruction, and new bone formation in patients with axial spondyloarthritis treated with TNF-α blockers.
Conclusion
The study found that successful treatment of inflammation in axial spondyloarthritis patients with TNF-α blockers is associated with new bone formation.
Supporting Evidence
- Serum levels of MMP-3, VEGF, and BALP were stable in TNF-α blocker-naïve patients over 2 years.
- Adalimumab treatment led to significant decreases in MMP-3 and VEGF levels.
- BALP levels increased significantly after 36 to 52 weeks of adalimumab treatment.
- A negative correlation was found between MMP-3 and BALP levels during treatment.
- VEGF levels correlated with disease activity indicators like CRP and BASDAI.
Takeaway
Doctors looked at blood markers in patients with a type of arthritis to see how treatment helps their bones heal.
Methodology
The study measured serum levels of MMP-3, VEGF, and BALP in TNF-α blocker-naïve and adalimumab-treated patients over specified time periods.
Limitations
The study may have limitations related to sample size and the specific cohorts analyzed.
Participant Demographics
The TNF-α blocker-naïve cohort had a mean age of 37.75 years, with 61.97% male and 81.69% HLA-B27 positive; the adalimumab-treated cohort had a mean age of 40.12 years.
Statistical Information
P-Value
P < 0.001 for BALP increase in treated patients
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website